Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
- PMID: 21830317
- PMCID: PMC3214247
- DOI: 10.1002/ppul.21525
Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
Abstract
Rationale: The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown.
Objectives: To determine if failure of antibiotic therapy to eradicate Pa and frequency of Pa recurrence are associated with increased exacerbation risk.
Methods: The cohort included 282 children with CF who participated in the EPIC trial ages 1-12 with newly acquired Pa, defined as either a first lifetime Pa positive respiratory culture or positive after two years of negative cultures (past isolation of Pa but >2 years prior to the trial). All received antibiotics to promote initial eradication followed by 15 months of intermittent maintenance antibiotics. Quarterly cultures were used to define initial eradication success and subsequent number of Pa recurrences. A standardized symptom-based definition of exacerbation was utilized. Cox proportional hazards models were used to estimate exacerbation risk.
Results: Failure to initially eradicate Pa was associated with exacerbation risk (hazard ratio [HR]: 2.49, 95% confidence interval [CI] 1.26, 4.93). In 245/282 with successful initial eradication during the trial, past isolation of Pa >2 years before the trial was the most significant predictor of exacerbation (HR 1.62, 95% CI 1.12, 2.35). In 37/282 who failed initial eradication, persistent Pa during the maintenance phase (1 or more Pa recurrences after failure to initially eradicate) added even greater exacerbation risk (HR 4.13, 95% CI 1.28, 13.32).
Conclusions: Children with CF who fail to eradicate after initial antibiotic treatment are at higher risk of subsequent exacerbation, suggesting clinical benefit to successful early eradication of Pa infection.
Copyright © 2011 Wiley Periodicals, Inc.
Figures


References
-
- Ratjen F, Döring G. Cystic fibrosis. Lancet. 2003;361:681–689. - PubMed
-
- Gibson RL, Burns JL, Ramsey BW. State of the art: pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918–951. - PubMed
-
- Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158–161. - PubMed
-
- Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol. 2007;42:525–532. - PubMed
-
- Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr. 2001;138:699–704. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 1UL1-RR025744/RR/NCRR NIH HHS/United States
- M01-RR02172/RR/NCRR NIH HHS/United States
- UL1 RR025780/RR/NCRR NIH HHS/United States
- 1UL1-RR025780/RR/NCRR NIH HHS/United States
- KL2 RR024977/RR/NCRR NIH HHS/United States
- UL1 RR025011/RR/NCRR NIH HHS/United States
- UL1 RR025014/RR/NCRR NIH HHS/United States
- UL1 TR001085/TR/NCATS NIH HHS/United States
- U01 HL080310/HL/NHLBI NIH HHS/United States
- UL1 RR024979/RR/NCRR NIH HHS/United States
- UL1 RR025005/RR/NCRR NIH HHS/United States
- UL1-RR025011/RR/NCRR NIH HHS/United States
- ULI-RR025014-03/RR/NCRR NIH HHS/United States
- UL1-RR0024979/RR/NCRR NIH HHS/United States
- TL1 RR024978/RR/NCRR NIH HHS/United States
- M01 RR002172/RR/NCRR NIH HHS/United States
- UL1 RR025744/RR/NCRR NIH HHS/United States
- UL1-RR025005/RR/NCRR NIH HHS/United States
- UL1RR025747/RR/NCRR NIH HHS/United States
- UL1 RR025747/RR/NCRR NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- 1UL-RR024975/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous